• Je něco špatně v tomto záznamu ?

Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry

M. Špinarová, J. Špinar, L. Špinarová, J. Krejčí, M. Goldbergová-Pávková, J. Pařenica, O. Ludka, F. Málek, P. Ošťádal, K. Benešová, J. Jarkovský, K. Lábr

. 2022 ; 58 (10) : . [pub] 20221018

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033035

Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF < 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 ± 9%. Statistically significant differences (p < 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (±0.55) nmol/L, with low dose (n = 113) 1-39 mg/day was 0.67 (±0.30) nmol/L, with mid dose (n = 202) 40-79 mg/day was 0.72 (±0.34) nmol/L, with high dose (n = 58) 80-119 mg/day was 0.85 (±0.40) nmol/L, and with maximum dose (n = 74) ≥120 mg/day was 1.07 (±0.76) nmol/L, p < 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p < 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033035
003      
CZ-PrNML
005      
20250415150323.0
007      
ta
008      
230120s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/medicina58101477 $2 doi
035    __
$a (PubMed)36295637
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Špinarová, Monika $u First Department of Internal Medicine-Cardioangiology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000332915160
245    10
$a Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry / $c M. Špinarová, J. Špinar, L. Špinarová, J. Krejčí, M. Goldbergová-Pávková, J. Pařenica, O. Ludka, F. Málek, P. Ošťádal, K. Benešová, J. Jarkovský, K. Lábr
520    9_
$a Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF &lt; 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 ± 9%. Statistically significant differences (p &lt; 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (±0.55) nmol/L, with low dose (n = 113) 1-39 mg/day was 0.67 (±0.30) nmol/L, with mid dose (n = 202) 40-79 mg/day was 0.72 (±0.34) nmol/L, with high dose (n = 58) 80-119 mg/day was 0.85 (±0.40) nmol/L, and with maximum dose (n = 74) ≥120 mg/day was 1.07 (±0.76) nmol/L, p &lt; 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p &lt; 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    12
$a adrenomedulin $7 D053607
650    _2
$a diuretika $7 D004232
650    _2
$a následné studie $7 D005500
650    _2
$a furosemid $x terapeutické užití $7 D005665
650    _2
$a inhibitory Na-K-Cl symportérů $7 D049994
650    _2
$a proteinové prekurzory $7 D011498
650    _2
$a peptidové fragmenty $7 D010446
650    _2
$a prognóza $7 D011379
650    _2
$a biologické markery $7 D015415
650    _2
$a hodnocení rizik $7 D018570
650    12
$a srdeční selhání $7 D006333
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
700    1_
$a Špinar, Jindřich $u First Department of Internal Medicine-Cardioangiology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Špinarová, Lenka, $d 1961-2025 $u First Department of Internal Medicine-Cardioangiology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000156446720 $7 xx0061415
700    1_
$a Krejčí, Jan $u First Department of Internal Medicine-Cardioangiology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Goldbergová-Pávková, Monika $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Pařenica, Jiří $u Department of Internal Cardiology Medicine, Faculty Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Ludka, Ondřej $u Department of Internal Medicine, Geriatrics and Practical Medicine, Faculty Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Málek, Filip $u Department of Cardiology, Na Homolce Hospital, 150 00 Prague, Czech Republic
700    1_
$a Ošťádal, Petr $u Department of Cardiology, Na Homolce Hospital, 150 00 Prague, Czech Republic
700    1_
$a Benešová, Klára $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Jarkovský, Jiří $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Lábr, Karel $u First Department of Internal Medicine-Cardioangiology, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000247388044
773    0_
$w MED00180386 $t Medicina $x 1648-9144 $g Roč. 58, č. 10 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36295637 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20250415150329 $b ABA008
999    __
$a ok $b bmc $g 1891668 $s 1184370
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 58 $c 10 $e 20221018 $i 1648-9144 $m Medicina $n Medicina (Kaunas) $x MED00180386
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace